<?xml version="1.0" encoding="UTF-8"?>
<document id="DDI-MedLine.d161">
    <sentence id="DDI-MedLine.d161.s0" text="Metabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys.&#xd;&#xa;">
        <entity id="DDI-MedLine.d161.s0.e0" charOffset="114-117"
            type="drug_n" text="MPTP"/>
    </sentence>
    <sentence id="DDI-MedLine.d161.s1" text="Degeneration of the dopaminergic nigrostriatal system and of noradrenergic neurons in the locus coeruleus are important pathological features of Parkinson's disease. "/>
    <sentence id="DDI-MedLine.d161.s2" text="There is an urgent need to develop therapies that slow down the progression of neurodegeneration in Parkinson's disease. "/>
    <sentence id="DDI-MedLine.d161.s3" text="In the present study, we tested whether the highly specific metabotropic glutamate receptor 5 antagonist, 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine, reduces dopaminergic and noradrenergic neuronal loss in monkeys rendered parkinsonian by chronic treatment with low doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. ">
        <entity id="DDI-MedLine.d161.s3.e0" charOffset="106-153"
            type="drug_n" text="3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine"/>
        <entity id="DDI-MedLine.d161.s3.e1" charOffset="281-324"
            type="drug_n" text="1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"/>
        <pair id="DDI-MedLine.d161.s3.p0" e1="DDI-MedLine.d161.s3.e0"
            e2="DDI-MedLine.d161.s3.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d161.s4" text="Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). ">
        <entity id="DDI-MedLine.d161.s4.e0" charOffset="21-64"
            type="drug_n" text="1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"/>
        <entity id="DDI-MedLine.d161.s4.e1" charOffset="150-197"
            type="drug_n" text="3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine"/>
        <entity id="DDI-MedLine.d161.s4.e2" charOffset="321-364"
            type="drug_n" text="1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"/>
        <entity id="DDI-MedLine.d161.s4.e3" charOffset="366-413"
            type="drug_n" text="3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine"/>
        <entity id="DDI-MedLine.d161.s4.e4" charOffset="422-465"
            type="drug_n" text="1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"/>
        <pair id="DDI-MedLine.d161.s4.p0" e1="DDI-MedLine.d161.s4.e0"
            e2="DDI-MedLine.d161.s4.e1" ddi="false"/>
        <pair id="DDI-MedLine.d161.s4.p1" e1="DDI-MedLine.d161.s4.e0"
            e2="DDI-MedLine.d161.s4.e2" ddi="false"/>
        <pair id="DDI-MedLine.d161.s4.p2" e1="DDI-MedLine.d161.s4.e0"
            e2="DDI-MedLine.d161.s4.e3" ddi="false"/>
        <pair id="DDI-MedLine.d161.s4.p3" e1="DDI-MedLine.d161.s4.e0"
            e2="DDI-MedLine.d161.s4.e4" ddi="false"/>
        <pair id="DDI-MedLine.d161.s4.p4" e1="DDI-MedLine.d161.s4.e1"
            e2="DDI-MedLine.d161.s4.e2" ddi="false"/>
        <pair id="DDI-MedLine.d161.s4.p5" e1="DDI-MedLine.d161.s4.e1"
            e2="DDI-MedLine.d161.s4.e3" ddi="false"/>
        <pair id="DDI-MedLine.d161.s4.p6" e1="DDI-MedLine.d161.s4.e1"
            e2="DDI-MedLine.d161.s4.e4" ddi="false"/>
        <pair id="DDI-MedLine.d161.s4.p7" e1="DDI-MedLine.d161.s4.e2"
            e2="DDI-MedLine.d161.s4.e3" ddi="false"/>
        <pair id="DDI-MedLine.d161.s4.p8" e1="DDI-MedLine.d161.s4.e2"
            e2="DDI-MedLine.d161.s4.e4" ddi="false"/>
        <pair id="DDI-MedLine.d161.s4.p9" e1="DDI-MedLine.d161.s4.e3"
            e2="DDI-MedLine.d161.s4.e4" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d161.s5" text="After 21 weeks of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment, all 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys were significantly affected. ">
        <entity id="DDI-MedLine.d161.s5.e0" charOffset="18-61"
            type="drug_n" text="1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"/>
        <entity id="DDI-MedLine.d161.s5.e1" charOffset="78-121"
            type="drug_n" text="1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"/>
        <entity id="DDI-MedLine.d161.s5.e2" charOffset="200-243"
            type="drug_n" text="1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"/>
        <entity id="DDI-MedLine.d161.s5.e3" charOffset="245-292"
            type="drug_n" text="3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine"/>
        <pair id="DDI-MedLine.d161.s5.p0" e1="DDI-MedLine.d161.s5.e0"
            e2="DDI-MedLine.d161.s5.e1" ddi="false"/>
        <pair id="DDI-MedLine.d161.s5.p1" e1="DDI-MedLine.d161.s5.e0"
            e2="DDI-MedLine.d161.s5.e2" ddi="false"/>
        <pair id="DDI-MedLine.d161.s5.p2" e1="DDI-MedLine.d161.s5.e0"
            e2="DDI-MedLine.d161.s5.e3" ddi="false"/>
        <pair id="DDI-MedLine.d161.s5.p3" e1="DDI-MedLine.d161.s5.e1"
            e2="DDI-MedLine.d161.s5.e2" ddi="false"/>
        <pair id="DDI-MedLine.d161.s5.p4" e1="DDI-MedLine.d161.s5.e1"
            e2="DDI-MedLine.d161.s5.e3" ddi="false"/>
        <pair id="DDI-MedLine.d161.s5.p5" e1="DDI-MedLine.d161.s5.e2"
            e2="DDI-MedLine.d161.s5.e3" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d161.s6" text="These behavioural observations were consistent with in vivo positron emission tomography dopamine transporter imaging data, and with post-mortem stereological counts of midbrain dopaminergic neurons, as well as striatal intensity measurements of dopamine transporter and tyrosine hydroxylase immunoreactivity, which were all significantly higher in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated animals than in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated monkeys. ">
        <entity id="DDI-MedLine.d161.s6.e0" charOffset="349-392"
            type="drug_n" text="1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"/>
        <entity id="DDI-MedLine.d161.s6.e1" charOffset="394-441"
            type="drug_n" text="3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine"/>
        <entity id="DDI-MedLine.d161.s6.e2" charOffset="467-510"
            type="drug_n" text="1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"/>
        <pair id="DDI-MedLine.d161.s6.p0" e1="DDI-MedLine.d161.s6.e0"
            e2="DDI-MedLine.d161.s6.e1" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d161.s6.p1" e1="DDI-MedLine.d161.s6.e0"
            e2="DDI-MedLine.d161.s6.e2" ddi="false"/>
        <pair id="DDI-MedLine.d161.s6.p2" e1="DDI-MedLine.d161.s6.e1"
            e2="DDI-MedLine.d161.s6.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d161.s7" text="The 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine treatment also had a significant effect on the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced loss of norepinephrine neurons in the locus coeruleus and adjoining A5 and A7 noradrenaline cell groups. ">
        <entity id="DDI-MedLine.d161.s7.e0" charOffset="4-51"
            type="drug_n" text="3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine"/>
        <entity id="DDI-MedLine.d161.s7.e1" charOffset="100-143"
            type="drug_n" text="1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"/>
        <pair id="DDI-MedLine.d161.s7.p0" e1="DDI-MedLine.d161.s7.e0"
            e2="DDI-MedLine.d161.s7.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d161.s8" text="In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals, almost 40% loss of tyrosine hydroxylase-positive norepinephrine neurons was found in locus coeruleus/A5/A7 noradrenaline cell groups, whereas the extent of neuronal loss was lower than 15% of control values in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys. ">
        <entity id="DDI-MedLine.d161.s8.e0" charOffset="3-46"
            type="drug_n" text="1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"/>
        <entity id="DDI-MedLine.d161.s8.e1" charOffset="283-326"
            type="drug_n" text="1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"/>
        <entity id="DDI-MedLine.d161.s8.e2" charOffset="328-375"
            type="drug_n" text="3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine"/>
        <pair id="DDI-MedLine.d161.s8.p0" e1="DDI-MedLine.d161.s8.e0"
            e2="DDI-MedLine.d161.s8.e1" ddi="false"/>
        <pair id="DDI-MedLine.d161.s8.p1" e1="DDI-MedLine.d161.s8.e0"
            e2="DDI-MedLine.d161.s8.e2" ddi="false"/>
        <pair id="DDI-MedLine.d161.s8.p2" e1="DDI-MedLine.d161.s8.e1"
            e2="DDI-MedLine.d161.s8.e2" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d161.s9" text="Our data demonstrate that chronic treatment with the metabotropic glutamate receptor 5 antagonist, 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine, significantly reduces 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity towards dopaminergic and noradrenergic cell groups in non-human primates. ">
        <entity id="DDI-MedLine.d161.s9.e0" charOffset="99-146"
            type="drug_n" text="3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine"/>
        <entity id="DDI-MedLine.d161.s9.e1" charOffset="171-214"
            type="drug_n" text="1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"/>
        <pair id="DDI-MedLine.d161.s9.p0" e1="DDI-MedLine.d161.s9.e0"
            e2="DDI-MedLine.d161.s9.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d161.s10" text="This suggests that the use of metabotropic glutamate receptor 5 antagonists may be a useful strategy to reduce degeneration of catecholaminergic neurons in Parkinson's disease."/>
</document>
